Health and Healthcare

Top 4 Biopharma Movers of the Past Week

Chris Lange

Published: February 28, 2016 10:40 am

Last Updated: January 13, 2020 12:36 pm

Over the past week, a few biotech companies made impressive runs. These moves were the result of positive trial results and a U.S. Food and Drug Administration (FDA) meeting. The companies 24/7 Wall St. has picked stood out from the rest with positive news guiding them last week. We have included information about each company, as well as recent trading activity and the consensus price target.

Ziopharm Oncology

A couple huge announcements from Ziopharm Oncology Inc. (NASDAQ: ZIOP) last week sent the stock soaring. The company said that the first patient has been dosed at the succeeding dose level in the its ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma or grade III malignant glioma. Earlier in the week, Ziopharm also announced the publication of a study in Scientific Reports describing the genetic editing of human leukocyte antigen in hematopoietic stem cells as a means of broadening the human application of these and other cell therapies.

Over the week, shares rose 29%, but they are down 9% year to date. Shares of Ziopharm traded at $7.84 on Friday’s close. The stock has a consensus analyst price target of $13.50 and a 52-week trading range of $4.56 to $14.93.

Trevena

Trevena Inc. (NASDAQ: TRVN) was one of the biopharma companies leading the bulls’ charge to start out last week. This movement came from the FDA granting a Breakthrough Therapy designation to the company’s lead product candidate, intravenous oliceridine (TRV130), for the management of moderate-to-severe acute pain. Following two successful Phase 2 studies, oliceridine is now in Phase 3 development. The Athena-1 safety and tolerability study is ongoing, with pivotal studies expected to begin in the second quarter of 2016.

Over the course of the week, shares rose 14%, but they are down 12% year to date. The stock was at $9.18 on Friday’s close. The consensus analyst target is $15.94, and the 52-week trading range is $5.06 to $13.57.

24/7 Wall St.
6 Companies That Destroyed Shareholders Last Week